Expert Interview
A Second Prescribing Update on Iovance’s Amtagvi (lifileucel) for Melanoma
Ticker(s): IOVA, REPLInstitution: University of Pennsylvania
- Serves as Professor of Medicine (Hematology-Oncology), Director of Clinical Research at the Tara Miller Melanoma Center, and Section Chief of Melanoma/Sarcoma at the Hospital of the University of Pennsylvania
- Treats hundreds of patients melanoma and prescribes Amtagvi once per month
- Research focuses on immune therapy, targeted therapy, phase I trials, combination therapy, experimental therapeutics, and pharmacology
Have you prescribed or referred any patients for treatment with Amtagvi (lifileucel) since its approval for advanced melanoma?
Added By: sara_adminHow would you compare Amtagvi’s clinical profile—particularly its efficacy and safety—to existing options like PD-1 inhibitors, CTLA-4 therapies, or combination regimens?
Added By: sara_adminHas REPL's recent delay or clinical setback affected your perception of the competitive landscape for melanoma?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
